US Bancorp DE Acquires 251 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

US Bancorp DE boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,951 shares of the biopharmaceutical company’s stock after purchasing an additional 251 shares during the quarter. US Bancorp DE’s holdings in Intra-Cellular Therapies were worth $582,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in ITCI. Headlands Technologies LLC bought a new stake in shares of Intra-Cellular Therapies during the first quarter valued at approximately $32,000. Summit Securities Group LLC purchased a new position in Intra-Cellular Therapies during the second quarter valued at $56,000. CWM LLC increased its holdings in Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 626 shares during the last quarter. EntryPoint Capital LLC lifted its stake in Intra-Cellular Therapies by 138.7% in the 1st quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 1,259 shares in the last quarter. Finally, Cetera Trust Company N.A boosted its holdings in shares of Intra-Cellular Therapies by 24.8% during the 3rd quarter. Cetera Trust Company N.A now owns 2,520 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 500 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at $2,229,876. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Sharon Mates sold 28,680 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $74.46, for a total value of $2,135,512.80. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $79,696,697.34. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Neumann sold 18,714 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 175,316 shares of company stock worth $13,037,345 in the last 90 days. 2.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ITCI shares. Royal Bank of Canada lifted their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. UBS Group decreased their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $97.23.

Intra-Cellular Therapies Trading Up 0.9 %

Shares of NASDAQ ITCI opened at $91.29 on Monday. Intra-Cellular Therapies, Inc. has a fifty-two week low of $52.88 and a fifty-two week high of $91.68. The business’s 50 day moving average price is $76.78 and its 200-day moving average price is $73.77.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.25) EPS. Analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.